全文获取类型
收费全文 | 1147篇 |
免费 | 105篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 107篇 |
妇产科学 | 9篇 |
基础医学 | 157篇 |
口腔科学 | 32篇 |
临床医学 | 104篇 |
内科学 | 238篇 |
皮肤病学 | 27篇 |
神经病学 | 65篇 |
特种医学 | 138篇 |
外科学 | 106篇 |
综合类 | 52篇 |
预防医学 | 78篇 |
眼科学 | 34篇 |
药学 | 57篇 |
肿瘤学 | 50篇 |
出版年
2021年 | 11篇 |
2020年 | 9篇 |
2019年 | 12篇 |
2018年 | 23篇 |
2017年 | 12篇 |
2016年 | 26篇 |
2015年 | 31篇 |
2014年 | 31篇 |
2013年 | 49篇 |
2012年 | 44篇 |
2011年 | 34篇 |
2010年 | 49篇 |
2009年 | 55篇 |
2008年 | 32篇 |
2007年 | 60篇 |
2006年 | 40篇 |
2005年 | 36篇 |
2004年 | 26篇 |
2003年 | 36篇 |
2002年 | 25篇 |
2001年 | 23篇 |
2000年 | 12篇 |
1999年 | 13篇 |
1998年 | 42篇 |
1997年 | 52篇 |
1996年 | 48篇 |
1995年 | 38篇 |
1994年 | 24篇 |
1993年 | 30篇 |
1992年 | 12篇 |
1991年 | 13篇 |
1990年 | 12篇 |
1989年 | 21篇 |
1988年 | 17篇 |
1987年 | 18篇 |
1986年 | 25篇 |
1985年 | 22篇 |
1984年 | 18篇 |
1983年 | 19篇 |
1981年 | 14篇 |
1980年 | 9篇 |
1979年 | 12篇 |
1977年 | 9篇 |
1976年 | 11篇 |
1973年 | 8篇 |
1972年 | 8篇 |
1971年 | 11篇 |
1970年 | 9篇 |
1967年 | 13篇 |
1965年 | 8篇 |
排序方式: 共有1262条查询结果,搜索用时 32 毫秒
81.
82.
83.
The relationship of cognitive flexibility with MMPI personality type, age, education, and IQ was investigated for a sample of 41 psychiatric inpatients. Cognitive flexibility was measured by the Weigl Color-Form Sorting Test. An index for measuring divergent thinking behavior was obtained from determining the similarity of their admission MMPI profiles to a MMPI prototype profile for divergent (psychotic) ideation using the formula: Divergent thinking = PA + PT + SC - L - K. Results showed that in this sample, cognitive flexibility was related significantly and inversely to the level of divergent thinking (p = .02), but was unrelated to IQ test scores. Supplemental analyses indicated that the level of divergent thinking may mask the established relationship of cognitive flexibility with age and education. 相似文献
84.
85.
ANDERSON G; COLES ET; CRANE M; DOUGLAS AC; GIBBS AR; GEDDES DM; PEEL ET; WOOD JB 《QJM : monthly journal of the Association of Physicians》1992,83(3):427-438
In order to describe the British experience of Wegener's granuiomatosisHospital Activity Analysis was used to collect cases diagnosedin England, Wales and Scotland between 1975 and 1985. Wherepossible clinical details, histological material and chest radiographswere obtained. Two hundred and sixty five patients were consideredto have Wegener's granuiomatosis. In 109 a single pathologistconfirmed the diagnosis by finding both granulomas and vasculitisin biopsy material. The diagnosis was made on clinical groundsor clinical grounds together with histological diagnosis inthe local hospital in 156 patients. Wegener's granuiomatosiswas confined to the lung or upper respiratory tract in 22 percent of patients and renal disease occurred in 58 per cent.Laboratory tests showed a pattern of mild anaemia, polymorphleucocytosis, eosinophilia and an elevated ESR and hypergammaglobulinaemia,with no specific pattern of changes. Histological confirmation was most frequently obtained by examinationof nasal biopsy specimens, but multiple biopsies were oftenrequired. Renal biopsies showed focal proliferative glomerulonephritisbut granulomatous glomerulonephritis was uncommon. Of availablechest radiographs 61 per cent were abnormal, large opacitiesbeing most common. Small irregular opacities were found lessoften and other abnormalities were uncommon. Treatment varied widely and 10 per cent of patients receivedno drug therapy. This large series illustrates that even withoutspecific treatment, patients with Wegener's granuiomatosis cansurvive for several years and with modern treatment survivalfor more than a decade is possible. Conclusions about the effectivenessof the various therapies cannot be drawn from this restrospectivestudy. Renal failure and disseminated vasculities were the commonestcauses of death; death was considered to result from complicationsof treatment with cytotoxic drugs or prednisolone in 6 per centof patients. 相似文献
86.
BACKGROUND: The Kell blood group system comprises 21 antigens residing on a red cell membrane glycoprotein of apparent M(r) 93,000. STUDY DESIGN AND METHODS: Serologic techniques were used to identify a new red cell antigen. The monoclonal antibody-specific immobilization of erythrocyte antigens (MAIEA) assay was used to identify the red cell membrane component carrying that antigen. RESULTS: A new high-frequency red cell antigen was identified and provisionally named RAZ. RAZ is absent from K.o red cells and from red cells treated with 2-amino- ethylisothiouronium bromide and is expressed weakly on McLeod phenotype cells. It differs from all other Kell system antigens, and no depression of other Kell system antigens on RAZ+ red cells was noticed. The RAZ antigen was shown by the MAIEA assay to be located on the Kell glycoprotein. CONCLUSION: RAZ is a new high-frequency antigen located on the Kell glycoprotein. The MAIEA assay is a very effective method of demonstrating the membrane structure carrying a red cell antigen. 相似文献
87.
Reid BJ Blount PL Rabinovitch PS 《Gastrointestinal endoscopy clinics of North America》2003,13(2):369-397
This article provides a framework for clinicians who are attempting the difficult task of interpreting the Barrett's biomarker literature with the goal of improving care for their patients. Although many articles. including more that 60 proposed biomarkers, have been published on this subject, only a few describe phase 3 and 4 studies that are of interest to the clinical gastroenterologist (Table 1). For year, dysplasia grade has been the sole means of risk stratification for patients with BE, and it likely will continue to be used in the foreseeable future. The current authors believe that dysplasia classification can be valuable using the team management approach and quality controls described previously. Significant problems, however, have emerged in phase 2 through 4 studies of dysplasia that make it imperative for the Barrett's field to incorporate additional biomarkers as they are validated. These problems include poor reproducibility of dysplasia interpretations, poor predictive value for negative, indefinite, and low-grade dysplasia, and inconsistent results for HGD in different centers, all of which makes it virtually impossible to develop national guidelines for surveillance. Some studies have even suggested that endoscopic biopsy surveillance using dysplasia may not be worthwhile. Currently, flow cytometric tetraploidy and aneuploidy have progressed furthest in biomarker validation (see Table 1). With proper handling, endoscopic biopsy specimens can be shipped to reference laboratories that have the instruments, computer analytic methods, and expertise to reproducibly detect tetraploidy and aneuploidy. The results of phase 4 studies indicate that flow cytometry appears to be useful in detecting a subset of patients who do not have HGD and yet have an increased risk of progression to cancer that cannot be identified by dysplasia grade. For many reasons, the authors anticipate that the number of validated biomarkers will increase substantially in the future. Biopsy repositories are now readily available for phase 3 studies that can evaluate and compare biomarkers. There are initiatives for multi-institutional Barrett's Centers of Excellence that could provide rapid progress in biomarker evaluation. In addition to new candidate biomarkers, the human genome project has provided high-throughput methodologies and methods for computer analysis of data, which can provide the volume and quality control required for clinically useful biomarkers. Currently, 17p (p53) LOH has progressed the furthest among molecular biomarkers. The authors do not recommend its routine clinical use at the present time, however. Finally, it is likely that clinicians will want to follow the results of clinical treatment-response studies and epidemiologic studies that evaluate relationship between clinical interventions or environmental risk and protective factors and surrogate endpoints, especially if the endpoints are progessing well along the phases of biomarker validation. These studies are likely to be of clinical interest because they may becoming the basis for randomized clinical trials to prevent cancer in BE. 相似文献
88.
89.
Can we identify termination of resuscitation criteria in cardiac arrest due to drowning: results from the French national out‐of‐hospital cardiac arrest registry 下载免费PDF全文
Hervé Hubert PhD Joséphine Escutnaire MSc Pierre Michelet MD PhD Evgéniya Babykina PhD Carlos El Khoury MD PhD Karim Tazarourte MD PhD Christian Vilhelm PhD Lahcen El Hiki PhD Benjamin Guinhouya PhD Pierre‐Yves Gueugniaud MD PhD on behalf GR‐RéAC 《Journal of evaluation in clinical practice》2016,22(6):928-935
90.